136 related articles for article (PubMed ID: 31266597)
1. Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma.
Osella-Abate S; Conti L; Annaratone L; Senetta R; Bertero L; Licciardello M; Caliendo V; Picciotto F; Quaglino P; Cassoni P; Ribero S
Pathology; 2019 Aug; 51(5):487-493. PubMed ID: 31266597
[TBL] [Abstract][Full Text] [Related]
2. Study of the immunophenotype of the inflammatory cells in melanomas with regression and halo nevi.
Botella-Estrada R; Kutzner H
Am J Dermatopathol; 2015 May; 37(5):376-80. PubMed ID: 25222195
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases.
Mourmouras V; Fimiani M; Rubegni P; Epistolato MC; Malagnino V; Cardone C; Cosci E; Nisi MC; Miracco C
Br J Dermatol; 2007 Sep; 157(3):531-9. PubMed ID: 17596146
[TBL] [Abstract][Full Text] [Related]
4. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
5. The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.
Gray A; Grushchak S; Mudaliar K; Kliethermes S; Carey K; Hutchens KA
Melanoma Res; 2017 Apr; 27(2):104-109. PubMed ID: 28125447
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
7. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of B-cell density in cutaneous melanoma.
Ladányi A; Kiss J; Mohos A; Somlai B; Liszkay G; Gilde K; Fejös Z; Gaudi I; Dobos J; Tímár J
Cancer Immunol Immunother; 2011 Dec; 60(12):1729-38. PubMed ID: 21779876
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.
Maibach F; Sadozai H; Seyed Jafari SM; Hunger RE; Schenk M
Front Immunol; 2020; 11():2105. PubMed ID: 33013886
[TBL] [Abstract][Full Text] [Related]
10. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
Erdag G; Schaefer JT; Smolkin ME; Deacon DH; Shea SM; Dengel LT; Patterson JW; Slingluff CL
Cancer Res; 2012 Mar; 72(5):1070-80. PubMed ID: 22266112
[TBL] [Abstract][Full Text] [Related]
11. Local immune response predicts survival in patients with thick (t4) melanomas.
Cintolo JA; Gimotty P; Blair A; Guerry D; Elder DE; Hammond R; Elenitsas R; Xu X; Fraker D; Schuchter LM; Czerniecki BJ; Karakousis G
Ann Surg Oncol; 2013 Oct; 20(11):3610-7. PubMed ID: 23838911
[TBL] [Abstract][Full Text] [Related]
12. Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.
Lin RL; Wang TJ; Joyce CJ; Mihm MC; Murphy GF; Lian CG; Lin JY
Melanoma Res; 2016 Oct; 26(5):524-7. PubMed ID: 26974966
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas.
Chłopik A; Selim MA; Peng Y; Wu CL; Tell-Marti G; Paral KM; Shalin SC; Kraft S; Hsu CK; Shea CR; Puig S; Fernandez-Figueras MT; Biernat W; Ryś J; Marszalek A; Hoang MP
Hum Pathol; 2018 Mar; 73():176-183. PubMed ID: 29307625
[TBL] [Abstract][Full Text] [Related]
14. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
de Moll EH; Fu Y; Qian Y; Perkins SH; Wieder S; Gnjatic S; Remark R; Bernardo SG; Moskalenko M; Yao J; Ferringer T; Chang R; Chipuk J; Horst BA; Birge MB; Phelps RG; Saenger YM
Cancer Immunol Immunother; 2015 Sep; 64(9):1193-203. PubMed ID: 26076664
[TBL] [Abstract][Full Text] [Related]
15. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
Hussein MR; Elsers DA; Fadel SA; Omar AE
J Clin Pathol; 2006 Mar; 59(3):316-24. PubMed ID: 16505286
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells.
Halliday GM; Patel A; Hunt MJ; Tefany FJ; Barnetson RS
World J Surg; 1995; 19(3):352-8. PubMed ID: 7638987
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
[TBL] [Abstract][Full Text] [Related]
18. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
[TBL] [Abstract][Full Text] [Related]
20. [Problems in defining melanoma regression and prognostic implication].
Requena C; Botella-Estrada R; Traves V; Nagore E; Almenar S; Guillén C
Actas Dermosifiliogr; 2009 Nov; 100(9):759-66. PubMed ID: 19889297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
